Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 169.53M P/E - EPS this Y -6.50% Ern Qtrly Grth -
Income -42.94M Forward P/E -3.69 EPS next Y -8.80% 50D Avg Chg -9.00%
Sales - PEG -0.03 EPS past 5Y - 200D Avg Chg -24.00%
Dividend N/A Price/Book 4.12 EPS next 5Y 86.40% 52W High Chg -60.00%
Recommedations 2.00 Quick Ratio 4.15 Shares Outstanding 36.68M 52W Low Chg 90.00%
Insider Own 3.67% ROA -39.45% Shares Float 35.28M Beta 1.72
Inst Own 22.92% ROE -122.46% Shares Shorted/Prior 7.14M/5.51M Price 5.50
Gross Margin - Profit Margin - Avg. Volume 948,230 Target Price 14.40
Oper. Margin - Earnings Date May 13 Volume 344,945 Change -3.34%
About PDS Biotechnology Corporation

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

PDS Biotechnology Corporation News
04/23/24 PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
03/30/24 PDS Biotechnology Corporation's (NASDAQ:PDSB) market cap dropped US$1.5m last week; individual investors who hold 59% were hit as were institutions
03/28/24 PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript
03/27/24 Q4 2023 PDS Biotechnology Corp Earnings Call
03/27/24 PDS Biotechnology Corp (PDSB) Reports Full Year 2023 Financial Results and Clinical Strategy Update
03/27/24 PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
03/20/24 PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
03/13/24 The 3 Most Undervalued Biotech Stocks to Buy in March 2024
03/13/24 PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
01/22/24 PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer
01/16/24 PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
01/02/24 All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy
12/04/23 PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/28/23 PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
11/15/23 PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2023 Earnings Call Transcript
11/14/23 PDS Biotechnology Corp (PDSB) Reports Increased Net Loss in Q3 2023 Amid Advancements in ...
11/14/23 PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
11/09/23 PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
11/07/23 PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results
10/23/23 PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO
PDSB Chatroom

User Image HK_Phooey Posted - 1 hour ago

$PDSB Sorry forgot the link: https://www.theguardian.com/society/2024/apr/26/cancer-mrna-vaccine-melanoma-trial

User Image HK_Phooey Posted - 1 hour ago

$PDSB UCLH (London) trials of a new mRNA melanoma vaccine underway combined with Keytruda. 49% reduction in mortality or the likelihood of the cancer returning. Could APC activator like Versammune improve this data?

User Image bull_goes_mooo Posted - 9 hours ago

$PDSB Retracement leg officially started with todays candle close

User Image minnesotafarmcountry Posted - 10 hours ago

$PDSB Interesting trading today, I see 🤔

User Image Ontherag Posted - 14 hours ago

$PDSB Rocket fuel has been increasing

User Image 809capital Posted - 15 hours ago

$HOOK my dude here butt still hurt from $PDSB banana on his 🍑 😂🤡😂🤡

User Image Edyy88 Posted - 16 hours ago

$PDSB hold 😈

User Image Fearless_Contrarian Posted - 16 hours ago

$PDSB Mr Frank, You can still do it. -PDSB investor

User Image DesertDweller93 Posted - 17 hours ago

$PDSB reminder of the early 2021 data for NCI triple combo trial. These data were reinforced as the trial matured and this ASCO presentation shows lots of details about the design, safety and efficacy on the first 25 patients, 18 of which were HPV16+. I am anticipating publication of updated data by this summer with a later cutoff than the 07/2023 cutoff reported on clinicaltrials.gov https://pdsbiotech.com/images/versamune/publications/Strauss_et_al_2021_American_Society_of_Clinical_Oncology_Annual_Meeting.pdf

User Image Stockman824 Posted - 17 hours ago

$PDSB I’m going to buy another 1,000 shares total. Bought 200 just now at 3.25. Let’s GO!!!

User Image minnesotafarmcountry Posted - 17 hours ago

$PDSB The open today is a green shoot … market imploding, and there were no pdsb sellers! 🙏

User Image 809capital Posted - 17 hours ago

@GermanJay wrong stock board. The one no one wants is $PDSB 🤪😂🤪😂

User Image Ontherag Posted - 20 hours ago

$PDSB Looks like HOOK is on the move. Ph2/3 trial design just announced. OS primary endpoint for phase 3. We need to get our trial launched asap. https://www.streetinsider.com/dr/news.php?id=23114247

User Image NorthWestHawk Posted - 21 hours ago

$MREO $HOOK $PDSB $EFTR

User Image Buttyboy Posted - 22 hours ago

$PDSB I can feeel it

User Image costap Posted - 1 day ago

$PDSB why is this so cheap

User Image NTS999 Posted - 1 day ago

$PDSB

User Image SaTwits Posted - 1 day ago

$PDSB green 3 days in a row, what is the world coming to?

User Image Water03 Posted - 1 day ago

$PDSB oct/nov/dec/jan/feb/march/april no partner no phase 3 or ability to fund what is going on ?

User Image Lovethespace27 Posted - 1 day ago

$PDSB Strong day so far 💪 like what I see … buytrigger @ 3,01$ gives a shortterm price range 3,40$-3,45$

User Image VarsityBlues69 Posted - 1 day ago

$PDSB we need volume bad

User Image Stockman824 Posted - 1 day ago

$PDSB read why Dr. Weiss is so involved in helping patients as well as the new areas he is interested in exploring to help his patients. IF we are able to succeed in developing new FDA approved cancer drugs we will become a major player in the oncology field. We have a ways to go but if our data continues to be as impressive as it has been then HOLD your shares for the next couple years and you will be very wealthy imo. Will there be a lot more ups and downs as well as giant potholes? Absolutely but do your OWN DD and know what you own, don’t listen to the outside noise!!! https://www.med.unc.edu/medicine/oncology/people/jared-weiss-md/

User Image Ontherag Posted - 2 days ago

$PDSB We are on the verge of a triple combo phase 3 trial with 2 unapproved drugs and maybe the potential of accelerated approval AND without ever testing all in combination together. Think about that, pretty remarkable if pulled off.

User Image TrkDvr Posted - 2 days ago

$PDSB I just started checking this stock out. Could someone point to what might have caused it to tank in March?

User Image Hmcraigg Posted - 2 days ago

$PDSB Nice bounce from the 2s. Longs are not out of the woods yet. Need material news to breakout and confirm.

User Image Stockman824 Posted - 2 days ago

$PDSB prevention of recurring or metastatic cancer is what really kills people the most, if we can prove that we can if not eliminate it but at least slow ctDNA then you will most likely start seeing bidding wars over our drugs and maybe even the entire company

User Image EddieH2020 Posted - 2 days ago

$PDSB I want to see Benchpresser post his position. Then I will be quiet.

User Image Rangudoc Posted - 2 days ago

$PDSB

User Image VarsityBlues69 Posted - 2 days ago

$PDSB someone tell @DubK to unblock me

User Image DesertDweller93 Posted - 2 days ago

@DubK @dvice2 @gth829c @Ontherag Important reminder to $PDSB investors of how incredible the V002 interim data were at 24 months. As you can see, back on 10/03/23 they were reviewing the data in relation to the triple combo to determine their path forward. https://pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/125-2023-news/878-iotechnnouncesnterim24onthurvivalateof7420231003

Analyst Ratings
B. Riley Securities Buy Mar 28, 24
HC Wainwright & Co. Buy Mar 27, 24
Oppenheimer Outperform Nov 15, 23
HC Wainwright & Co. Buy Oct 11, 23
HC Wainwright & Co. Buy Sep 27, 23
HC Wainwright & Co. Buy Sep 20, 23
HC Wainwright & Co. Buy Aug 14, 23
HC Wainwright & Co. Buy Jun 6, 23
Oppenheimer Outperform May 26, 23